NCT02842125: Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

NCT02842125
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: Patient must have measurable evidence of liver metastases; Patient must have received at least 1 prior standard of care treatment in the metastatic setting & had tumor progression within 3 months
Exclusions: Patients with brain metastases or irradiated stable brain metastases; Patients who are candidates for locoregional therapy of liver
https://ClinicalTrials.gov/show/NCT02842125

Comments are closed.

Up ↑